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Abstract 
Imidazole acts as a heme-site inhibitor of nitric oxide synthase (NOS). We used this compound to investigate whether the substrate L-arginine binds 
directly to the heme or to a separate domain of brain NOS. Enzyme kinetic experiments howed that imidazole enhanced the apparent K,,, for 
t-arginine without affecting maximal enzyme activity, and binding studies revealed that the inhibitor displaced the radioligand p-nitro-t-[‘Hlarginine 
in a concentration-dependent fashion. These results demonstrate that imidazole exerts its effects on NOS in an L-arginine-competitive manner and 
that the substrate site of the enzyme may be identical with the prosthetic heme group. 
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1. Introduction 
Nitric oxide synthase (NOS) isozymes catalyze oxida- 
tion of the guanidino group of L-arginine to NO and 
L-citrulline [l-3]. The reaction involves activation of mo- 
lecular oxygen by a cytochrome P,,,-like heme group 
located in the catalytic center of the enzyme [47] and 
requires the pteridine H,biopterin as a cofactor [8-lo]. 
Reduction of oxygen requires NADPH-derived electrons 
shuttled to the heme by a flavin-containing reductase 
domain, and this electron transfer appears to represent 
the calmodulin-dependent s ep of NO synthesis [11,12]. 
The reductase activity of NOS can be assayed independ- 
ently of NO synthesis, because the flavins also reduce 
exogenously added acceptor molecules such as cyto- 
chrome c or nitroblue tetrazolium [l 11. When brain NOS 
is activated by Ca2’/calmodulin in the presence of 
subsaturating concentrations of L-arginine or H,biop- 
terin, electron transfer from NADPH to the heme still 
proceeds, but uncoupling of oxygen activation from sub- 
strate metabolism results in the generation of superoxide 
anions and hydrogen peroxide under these conditions 
[13-161. 
As a cytochrome Pd5,,, NOS is inhibited by imidazole 
and various imidazole derivatives [7,17]. It has been 
shown that recombinant rat brain NOS exhibits type II 
difference spectra upon binding of imidazole, indicative 
of the occurrence of a low spin heme species 1181. This 
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ine; H,biopterin, (6R)-5,6,7,8-tetrahydro+biopterin; IC,,, concentra- 
tion producing half-maximal inhibition. 
effect of imidazole has been attributed to displacement 
of a bound, as yet uncharacterized ligand of the heme. 
We recently found that 7-nitro-indazole, another puta- 
tive heme-site inhibitor of NOS, antagonized both sub- 
strate and H,biopterin binding to the purified brain en- 
zyme, suggesting that the pteridine site of the enzyme 
may be located proximal to the heme [19]. The present 
study was performed to investigate: (i) whether imidazole 
binds to the substrate site of NOS; and (ii) whether the 
unknown ligand displaced from the enzyme by imidazole 
is identical with H,biopterin. 
2. Materials and methods 
2.1. Materials 
NOS was purified from porcine brain as previously described [IO]. 
L-[2,3,4,5-‘H]Arginine hydrochloride (57 Ci/mmol) and NG-nitro-L- 
[2,3,4,5-‘Hlarginine hydrochloride (59 Ci/mmol) were purchased from 
MedPro (Amersham), Vienna, Austria. Labelled L-arginine was puri- 
fied monthly by cation exchange HPLC with 50 mM sodium acetate 
(pH 6.5) as eluent to reduce blank levels in the citrulline assay. 
3’-[3H](6R)-5,6,7,8-Tetrahydro-L-biopterin was synthesized enzymati- 
tally from [8,5’-‘H]GTP [20], unlabelled H,biopterin was obtained from 
Dr. B. Schircks Laboratories, Jona, Switzerland. Stock solutions of 
imidazole (1 M) were adjusted to pH 7.0 with hydrochloric acid and 
diluted with H20. All other chemicals were from Sigma, Deisenhofen, 
Germany. 
2.2. Determination of NOS activities 
NOS activity was determined as formation of L-[3H]citrulline from 
L-[‘Hlarginine. Unless otherwise indicated, purified brain NOS (0.1-0.5 
pug) was incubated in total volumes of 0.1 ml for 10 min at 37°C in the 
presence of 50 mM triethanolamine/HCl buffer (pH 7.0), 0.1 mM 
L-[‘Hlarginine (50,000-70,000 cpm), 0.5 mM CaCl,. 10 &ml calmod- 
ulin, 0.2 mM NADPH, 10 PM H,biopterin, 5 PM FMN, and 5 PM 
FAD. [3H]Citrulline was separated from rH]arginine by chromatogra- 
phy over a Dowex 50W cation exchange resin, and radioactivity was 
determined by liquid scintillation counting. Blanks were determined in 
the absence of enzyme. For calculation of enzyme activities, total 
amounts of L- [3H]citrulline formation were corrected for blank levels 
and recovery (83 + 3% as determined with authentic L-[‘4C]citrulline). 
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NOS-catalyzed formation of HZO, and reduction of cytochrome c were 
assayed spectrophotometrically against calmodulin-deficient blanks as 
previously described [11,14]. 
2.3. Binding studies 
Protein binding studies were performed as described [19,21]. Briefly, 
purified brain NOS (2-4 pug) was incubated for 10 min at 37°C with a 
fixed concentration of the radioligand (20 nM [‘H]H,biopterin, 18 nCi 
or 10 nM NG-nitro-L-[2,3,4,5-SH]arginine, 60 nCi) in 0.1 ml of 50 mM 
triethanolamine/HCl buffer (pH 7.0). Saturation experiments were per- 
formed in the presence of increasing concentrations of the respective 
unlabelled ligands. Separation of bound from free radioligand was 
performed by polyethylene glycol precipitation and rapid vacuum fil- 
tration over Whatman glass fiber filters (GFIB). Radioactivity on the 
filters was determined by liquid scintillation counting. 
2.4. Data evaluation 
Enzyme kinetic parameters were calculated from individual double- 
reciprocal plots. Data obtained from binding experiments were ana- 
lyzed by the GIPMAX non-linear least-squares regression curve fitting 
program [22] to obtain equilibrium constants. All data are mean val- 
ues f S.E.M. of three experiments. 
3. Results 
To investigate the mechanisms accounting for inhibi- 
tion of brain NOS by imidazole, we have compared the 
effects of the drug on three different catalytic activities 
of the purified enzyme: (i) formation of L-citrulline from 
L-arginine; (ii) formation of H,O, in the absence of L- 
arginine; and (iii) reduction of cytochrome c. As shown 
in Fig. 1, imidazole seemed to be a less potent inhibitor 
in the citrulline assay as compared to its effects on un- 
coupled oxygen activation. Cytochrome c reduction was 
not affected by up to 10 mM imidazole, confirming that 
this compound does not interfere with redox-cycling of 
the Aavins [17]. Complete concentration-response curves 
recorded in the presence of 0.1 mM L-arginine (not 
shown) revealed an IC,, value for inhibition of L-cit- 
rulline formation of 6.2 2 0.58 mM, whereas approxi- 
mately 20- fold lower concentrations of the drug were 
sufficient to block generation of H,O, (I(& = 83 + 38 
PM). Since formation of H,O, was measured in the ab- 
sence of both L-arginine and H,biopterin, the data indi- 
cated to us that imidazole may compete for either sub- 
strate or pteridine binding to NOS. Thus, we have per- 
formed enzyme kinetic experiments to settle the type of 
NOS inhibition by imidazole as well as binding studies 
using labelled L- NNA and H,biopterin as radioligands 
[19,21] to see whether the drug interferes with substrate 
or pteridine binding. For enzyme kinetics, formation of 
L-citrulline was measured in the presence of l-100 ,LM 
L-arginine with and without 1 mM imidazole. The repre- 
sentative double-reciprocal plot shown in Fig. 2 identi- 
fied imidazole as a purely competitive inhibitor of brain 
NOS. Evaluation of the data revealed an apparent K,,, for 
L-arginine of 6.4 f. 0.65 ,LLM, which was increased about 
4-fold to 23.6 + 3.12 ,uM by 1 mM imidazole, whereas 
v,,,.., was not significantly affected (0.62 + 0.041 and 
0.56 + 0.076 pmol L-citrulline.mg-' .min-’ in the ab- 
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sence and presence of 1 mM imidazole). From five indi- 
vidual plots we have calculated a kinetic K, of 390 + 45 
PM. 
These data pointed to a purely L-arginine-competitive 
type of NOS inhibition by imidazole, but this was in 
apparent conflict with previous work reporting the oppo- 
site, i.e. purely non-competitive actions of the drug 
[ 17,181. Since recent work from our laboratory demon- 
strated that L-[3H]NNA is a useful tool for reversible 
labelling of the substrate site of NOS in protein binding 
studies [21], we applied this method for competition ex- 
periments with imidazole to substantiate and extend the 
observations made in functional studies. As shown in 
Fig. 3 (filled symbols), imidazole antagonized binding of 
L-[3H]NNA in a concentration-dependent manner with 
an IC,, of approximately 0.1 mM. Analysis of the data 
with the GIPMAX non-linear least-squares regression 
curve fitting program [22] yielded a K, of 198 +_ 63 ,uM 
imidazole. Saturation experiments revealed that imi- 
dazole reduced the affinity of NOS for the radioligand 
but had no effect on maximal binding (not shown). Fi- 
nally, we used 3H-labelled H,biopterin as a radioligand 
to test for possible effects of imidazole on pteridine bind- 
ing. However, as shown in Fig. 3 (open symbols), the 
drug was an only weak antagonist of [3H]H,biopterin 
binding and produced about 50% inhibition at 100 mM 
with an estimated K, of -50 mM. 
4. Discussion 
Inhibition by imidazole of reactions involving the P450- 
like heme moiety of brain NOS and lack of effect on 
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Fig. 1. Effects of imidazole on different catalytic activities of brain 
NOS. Formation of L-citrulline (filled) and H,O, (hatched) as well as 
reduction of cytochrome c (open) were determined in the presence of 
the indicated concentrations of imidazole as described in section 2.2. 
Results are expressed as percent of enzyme activities determined in the 
absence of imidazole and represent means + S.E.M. of three experi- 
ments. 
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Fig. 2. Double-reciprocal plot of L-arginine concentration (I-100 ,uM) 
versus L-citrulline formation by brain NOS. Data are representative for 
five similar experiments. 
reduction of cytochrome c is in agreement with previous 
reports describing the effects of imidazole or various 
imidazole derivatives on NOS and other cytochromes 
Pds,, [7,17,23-271, The present study suggests that binding 
of imidazole to the prosthetic heme group of brain NOS 
is competitive with the substrate L-arginine. This is evi- 
dent from enzyme kinetic experiments and from binding 
studies showing that imidazole enhanced the apparent 
Km for L-arginine and antagonized L-[3H]NNA binding, 
respectively, whereas V,,,,, and binding of H,biopterin 
were not markedly affected by the drug. The calculated 
kinetic K, (390 ,LLM) for inhibition of citrulline formation 
is in accordance with the affinity constant obtained in 
binding studies (200 ,uM) and with the IC,, for inhibition 
of H,O, formation (280 ,uM). The latter enzyme activity 
was assayed in the absence of t,-arginine and may there- 
fore reflect directly the affinity of imidazole for brain 
NOS. The equilibrium constants we have determined are 
similar to the K, value reported for inhibition of purified 
bovine brain NOS [ 171 and to the spectral binding con- 
stant of the drug determined with the purified recombi- 
nant rat brain enzyme [18]. 
Imidazole also antagonized [3H]H,biopterin binding, 
but this effect became significant at high concentrations 
only and may therefore not contribute to inhibition of 
NOS activity. These data also render it unlikely that 
H,biopterin represents the unidentified ligand of the 
heme McMillan et al. have proposed to be displaced by 
imidazole [18]. Since recent results point to an allosteric 
interaction of the substrate and pteridine domains of 
NOS [19], it may be concluded that the effect of imi- 
dazole on [3H]H,biopterin binding results from binding 
of the drug to the heme site rather than from a direct 
interaction with the pteridine binding domain. 
Miconazole and other imidazole derivatives were iden- 
tified as purely competitive inhibitors of steroid aroma- 
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tase [24], and several related compounds were found to 
be competitive or mixed-type inhibitors of various cyto- 
chrome Pds,, mediated hydroxylation reactions [25-271. 
Thus, substrate-competitive inhibition of a cytochrome 
P,,, by imidazole or its derivatives is not surprising per 
se. However, our results are in conflict with two previous 
studies which have described imidazole as purely non- 
competitive inhibitor of brain NOS [17,18]. We have 
considered several possible explanations for this intrigu- 
ing discrepancy but obtained no experimental evidence 
to support them. Importantly, different NOS prepara- 
tions were used in each of the pertinent studies, and in 
a recent abstract Dawson et al. reported on the identifi- 
cation of two novel isoforms of neuronal NOS [28]. It 
may be speculated, therefore, that the enzyme we have 
used represents adistinct NOS isoform. However, exper- 
iments performed with purified rat brain NOS and crude 
cytosols of RAW 264.7 macrophages confirmed the pres- 
ent data obtained with the porcine enzyme (unpublished 
results). Moreover, virtually identical biochemical prop- 
erties have been reported so far for neuronal NOS 
prepared from various sources (for reviews see [l-3]). 
Alternatively, different protocols applied for enzyme pu- 
rification could account for the observed differences, but 
this is unlikely because similar results were obtained 
when the initial ammonium sulfate precipitation step was 
omitted and the ADP-Sepharose eluate was chromato- 
graphed over a gel filtration column as final purification 
step (not shown). Thus, at present we are unable to pro- 
vide a reliable explanation for the controversial results, 
but future studies using other NOS preparations and 
additional biochemical methods may shed light on this 
issue. 
In summary, our results demonstrate that imidazole 
, , , , ,\ 
0 10-7 10-5 10-s 10-r 
Imidazole (M) 
Fig. 3. Effects of imidazole on binding of L-[ZH]NNA (0) and [‘H]H,bi- 
opterin (0) to brain NOS. Protein binding studies were carried out in 
the presence of increasing concentrations of imidazole as described in 
section 2.2. Data are expressed as percent of radiohgand binding deter- 
mined in the absence of imidazole and represent mean values + S.E.M. 
of three experiments. 
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inhibits heme-catalyzed activities of NOS and binds to 
the enzyme isolated from porcine brain in an L-arginine- 
competitive manner, indicating that the substrate site of 
NOS may be identical with the prosthetic heme group. 
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